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Abstract 
Introduction: In many countries uptake of colorectal cancer (CRC) screening remains low.  
Aim: To assess how procedural characteristics of CRC screening programmes determine preferences 
for participation and how individuals weigh these against the perceived benefits from participation in 
CRC screening. 
Methods: A discrete choice experiment was conducted among subjects in the age-group of 50 – 75 
years, including both screening-naïve subjects as well as participants of a CRC screening programme. 
Subjects were asked on their on preferences for aspects of CRC screening programmes using 
scenarios based on: pain, risk of complications, screening location, preparation, duration of procedure, 
screening interval and risk reduction of CRC related death.  
Results: The response was 31% (156/500) for screening-naïve and 57% (124/210) for CRC screening 
participants. All aspects proved to significantly influence the respondents’ preferences. For both 
groups combined, respondents required an additional relative risk reduction of CRC related death by a 
screening programme of 1% for every additional 10 minutes of duration, 5% in order to expose 
themselves to a small risk of complications, 10% to accept mild pain, 10% to undergo preparation with 
an enema, 12% to use 0.75 litres of oral preparation combined with 12 hours fasting and 32% to use 
an extensive bowel preparation. Screening intervals shorter than 10 years were significantly preferred 
to a 10-year screening interval. 
Conclusion: This study shows that especially type of bowel preparation, risk reduction and length of 
screening interval influence CRC screening preferences. Furthermore, improving awareness on CRC 
mortality reduction by CRC screening may increase uptake.   
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Introduction 
Colorectal carcinoma (CRC) is the second most frequently occurring malignancy in the European 
Union, and the second leading cause of cancer related death in the Western world. (1) A recent study 
demonstrates that for many European countries CRC mortality rates are decreasing while incidence is 
rising, suggesting an increasing CRC prevalence. (2) CRC screening is effective in reducing CRC 
mortality. (3-11) Screening can reduce CRC mortality by early detection of CRC and endoscopic 
removal of premalignant precursors of CRC (adenomas). (5;11;12) There are several methods 
available for CRC screening. The various types of faecal occult blood tests (FOBTs) primarily aim at 
the early detection of CRC, whereas endoscopic and radiologic screening tests (flexible 
sigmoidoscopy (FS), colonoscopy) are effective at both early detection and removal of premalignant 
lesions. (12) Different screening methods are expected to have a different impact on CRC mortality 
reduction due to these differences in preventive potential. CRC screening methods also differ with 
respect to procedural characteristics, which determine the subject’s burden of a screening method. 
CRC screening methods perceived as the most burdensome (FS, colonoscopy) also have the largest 
potential for prevention of CRC. (12) Currently, insufficient evidence is available to recommend one 
screening method over another.  
Attendance is an important determinant of the effectiveness of CRC screening programmes. 
Uptake of CRC screening in a pilot screening programme in the Netherlands has remained lower than 
uptake of breast and cervical cancer screening. (13-15) In many other countries, uptake of CRC 
screening, as well as continuing adherence to CRC screening, has also remained suboptimal. 
(3;4;13;16-18) It has been established that increasing colorectal cancer screening uptake, in 
comparison with other targets, has a large potential for reducing CRC related mortality. (19) 
Attendance rates depend on the willingness of individuals to undergo a certain screening test. This 
willingness may be influenced by perceived advantages and drawbacks of CRC screening tests and 
furthermore, by knowledge and awareness of CRC, CRC risk and CRC screening (18;20;21).  
Individuals may be willing to undergo a screening test despite several drawbacks in order to maximize 
health benefit or vice versa (to accept a lower health benefit in order to avoid several burdensome test 
characteristics). To optimise a CRC screening programme it is of paramount importance to gain 
insight in factors that influence population preferences for CRC screening programmes, and the trade-
offs individuals are willing to make between benefits and drawbacks of a CRC screening programme. 
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Research has shown that patient preferences can have a major impact on their willingness to use 
services and furthermore, there is an increasing emphasis on involvement of patients in health care 
decisions. (22)   
This study therefore investigated preferences for CRC screening using a discrete choice 
experiment (DCE). DCE is a survey methodology with its origin in market research. DCEs are widely 
used for the assessment of preferences in transport and environmental economics and marketing 
research. (23) They are increasingly used for health care purposes. (24;25)  
It has been demonstrated that awareness of CRC and CRC screening in the Netherlands has 
remained low. (21) There is currently no organised CRC screening programme in the Netherlands, 
except for hereditary or familial CRC. A similar situation is encountered in many countries in the EU, in 
fact, only approximately 50% of the target population is offered any type of screening for CRC. It is of 
particular importance to study preferences in a screening naïve population, since they may guide the 
introduction and adjustment of new CRC screening programmes in these countries.  
The aim of our study was to determine how procedural characteristics of various CRC 
screening methods determine preferences for participation, and how individuals weigh these against 
the expected health benefits from CRC screening. We compared the relative importance of aspects of 
the three most commonly used CRC screening tests: FOBT, FS and colonoscopy.  
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Materials and methods  
 
Study population 
We conducted the study in two groups. The first group included a total of 500 screening-naïve 
individuals aged 50-74 years old who were randomly selected from the population registry of the 
region Rijnmond in the Southwest of the Netherlands. The region includes Rotterdam and surrounding 
suburbs and harbours 338.000 inhabitants in the target age groups. The second group included 210 
participants of a randomised screening trial for CRC in the Netherlands from the same target 
population as mentioned above. This screening trial invited average risk individuals to participate in a 
CRC screening programme with guiac-based FOBT (gFOBT), faecal immunochemical test (FIT) or 
FS. (13) 
 
Invitation of subjects 
Subjects were contacted by mail. They received a questionnaire and an information brochure with 
general and background information about CRC and CRC screening. Individuals could return the 
questionnaire in a postage-paid self-addressed envelope that was included in the mailing package. A 
reminder was sent four weeks later in case of non-response.  
 
DCE 
DCE is a formal technique to assess preferences, assuming that a healthcare intervention (e.g. a 
screening programme) can be described by its characteristics (attributes; e.g. test duration). (26) 
Those attributes are further specified by variants of that attribute (levels; e.g. for test duration: 10, 20, 
30 minutes). The DCE assumes that the individual preference for a test is determined by the levels of 
those attributes. (26) Individuals are presented with a number of choice sets containing several 
scenarios (screening programmes). Those programmes are described by several attributes with 
varying levels (Figure 1). The results of a DCE provide information on the relative importance of the 
attributes and the trade-offs individuals are willing to make between these attributes. The DCE design 
will be explained in more detail further on.  
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Attributes and attribute levels  
The attributes and attribute levels of the DCE were derived from literature review, expert opinions, 
interviews with screening naïve (n=10) and screened (n=10) individuals of the target population. In the 
interviews we asked individuals to point out which of these attributes they expected to be important or 
had been important in their decision to participate in a CRC screening programme. The attributes 
identified as most relevant were: pain, risk of complications, location of the screening test, preparation 
for the procedure, duration of the procedure, screening interval and risk reduction of CRC related 
death (Table 1). Attribute levels were derived from the literature. The levels for each attribute 
incorporated the range of characteristics or possible test outcomes of all different screening methods 
(FOBT, FS and colonoscopy). The attribute ‘interval’ was related to a CRC screening programme, the 
other attributes were test-related. 
 
Study design and questionnaire 
The design contained three attributes with two levels and four attributes with four levels. The 
combination of those attributes and levels resulted in 2048 (i.e. 23*44) possible test scenarios. Since it 
is not feasible to present a single individual with all these scenarios, we reduced the model to 16 
scenarios (a fractional factorial design) by means of a website, containing a library of orthogonal 
arrays. (27) These 16 scenarios were used to create 16 choice sets. Each choice set contained two 
screening programmes and an opt-out (the option to choose ‘no screening’, see figure 1). A special 
technique (fold-over; (28)) was used to create the second programme of each choice set. As a result, 
our design was an efficient orthogonal design; there was no correlation between any pairs of attributes 
(orthogonality), all levels of each attribute were represented in the same frequency (level balance), 
and similar levels of an attribute did not occur within the same choice set (minimal overlap). A 
rationality test was included in the DCE to investigate the understanding of the questionnaire. This 
was a choice set of which one screening programme was logically preferable over the other given the 
attribute levels. 
The questionnaire further contained questions on background variables (e.g. generic health 
status (EQ-5D; (29))) and a question assessing experienced difficulty of the questionnaire (5-point 
scale). A written description of the attributes and levels was given at the beginning. We conducted a 
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pilot study (n=20) to ascertain respondents could manage the length of the questionnaire and to 
examine the intelligibility, acceptability and validity of the questionnaire.  
 
The study was approved by the Medical Ethical Committee of the Erasmus MC (MEC-2007-
224). 
 
Analyses  
Each choice between three options (two screening programmes and the opt-out) was considered as a 
specific observation. A multinomial logit model was used to analyse the data. We excluded individuals 
who answered less than 13 questions of the DCE. 
We assumed that there was no linear relationship between the different levels of the attributes 
‘preparation’ and ‘screening interval’ and that all attributes had independent effects on preferences. 
On this basis, we estimated the following model for the DCE:  
 
U=  V + ε = β0 + β1 pain + β2 complications + β3 location + β4 enema + β5 0,75lfluid + β6 4lfluid + β7 duration + β8 interval2+ β9 
interval5 + β10 interval10 + β11 mortalityreduction + ε 
 
U represents latent utility of a CRC screening alternative in a choice set. It is assumed that an 
individual will choose the CRC screening alternative which maximises his/her utility amongst all 
alternatives in a choice set. V is a systematic, explainable, component specified as a function of the 
attributes of the CRC screening alternatives. ε is the random (unexplainable) component representing 
unmeasured variation in preferences. The constant term (screening programme; β0) is an ‘alternative 
specific constant’ and indicates the relative weight individuals place on screening programmes 
compared to no screening. β1-β11 are coefficients of the attributes indicating the relative weight 
individuals place on a certain attribute(level). The value of each coefficient represents the importance 
respondents assign to a certain level. However, different attributes utilise different units of 
measurement. For example, the coefficient for ‘risk reduction of death from CRC’ represents the 
importance per relative 10% risk reduction. When looking at a screening programme that generates a 
50% risk reduction, the coefficient should be multiplied five times in order to enable comparison to the 
coefficients of other levels. An attribute with a two sided p-value smaller than 0.05 was considered to 
be important in the decision to participate in a certain screening programme. 
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Given the current DCE literature (30;31), further sensitivity analyses were conducted to 
explore the impact of excluding respondents who failed the rationality test by removing such 
individuals from the sample and rerunning the analysis.  
The trade-offs respondents were willing to make between the attributes were calculated by the 
ratios of the coefficients of the different attributes with risk reduction as the denominator. For example, 
β1/β11 indicates how much additional relative risk reduction respondents think a test should generate in 
order to undergo a test that causes mild pain instead of a test that causes no pain.  
To examine the expected uptake of CRC screening based on our results, we applied the 
model as presented by Gerard and colleagues and Hall and colleagues to our data. (32;33)  
                           1              
                    (1+e^-V) 
The model assumes that a preference score of 0 indicates that individuals have an equal 
preference for either participation or non-participation, hence the expected participation rate equals 
50%. Additionally, we investigated the effect of changing the most important CRC screening 
programme characteristics, as identified by the results of our multinomial logit model, on the expected 
uptake of CRC screening. The average probability of participation was calculated by entering the 
constant term (β0) into the model as described above.  
The expected uptake of the different screening tests was calculated by adding up the different 
levels corresponding with the screening test concerned, and entering this value into the model. The 
levels we applied for assessing the uptake of FOBT were ‘no pain’, no risk of complications, location 
‘at home’, no preparation and a duration of 15 minutes. For FS we applied ‘mild pain’, a small risk of 
complications, location ‘hospital’, preparation by an enema and a duration of 30 minutes. For 
colonoscopy we used ‘mild pain’, a small risk of complications, location ‘hospital’, preparation by 
‘drinking of 4 litres of fluid and a duration of 90 minutes.   
The influence of the different levels on expected uptake was calculated by entering the 
coefficients of the levels, added to the constant term, into the model.  
Aggregate data on socio-economic status (SES) were available at the level of the 
respondents’ area zip code, weighted by the number of inhabitants per postal code and classified into 
three groups (high, average, low).  
Characteristics of the different groups were compared using parametric and non-parametric 
tests. For categorical data, we used Chi-square and Fisher Exact Test to test for differences between 
Pparticipation =   
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screening naïve individuals and CRC screening participants. For continuous variables, we used the 
Independent Samples T-Test. To assess whether there were differences in preferences among 
participants of the FOBT (either gFOBT or FIT) and FS screening programme and those with and 
without endoscopy experience, we performed subgroup analyses. For comparing subgroups, we 
included all respondents in the same model and used the subgroup as interaction term. 
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Results 
Respondents 
The response rate was higher among CRC screening participants (59%; 124/210) compared to 
screening naïve individuals (31%; 156/500) (Table 2). The characteristics of the respondents are 
shown in Table 2. Among the screening naïve group, 22% had undergone an endoscopy in the past. 
Within the group of CRC screening participants, 53% had previous endoscopy experience including 
22% (16/72) of FOBT screenees and logically all FS screening subjects (48/48).  
 
DCE results 
Forty-three percent of the screening-naïve individuals and 50% of the CRC screening participants 
rated the questionnaire as ‘easy’ (p=0.24).  
The signs of all coefficients of the attributes were consistent with our initial hypotheses (see 
Table 3). The positive sign given to the coefficient ‘risk reduction of death from CRC’ indicated that 
respondents preferred a test generating a higher risk reduction over a test that generates a lower risk 
reduction. The positive sign of the coefficients for shorter screening intervals indicated that individuals 
preferred those screening intervals over screening once every 10 years. The negative signs for all 
other attributes indicate that individuals preferred a screening test of shorter duration, with no 
preparation, no pain and no risk of complications.  
The non-significant coefficient of the constant term in the screening-naïve group indicated that 
these subjects had, if assuming a screening programme with the reference level for all the attributes, 
no preference for either screening or no screening whereas the group of CRC screening participants 
expressed a positive attitude towards screening compared to no screening (positive significant 
coefficient). All screening attributes proved to be important determinants of the preferences in each of 
the respondent groups, except for location of the screening test, which only significantly influenced 
preferences of CRC screening participants and not those of the screening naïve individuals and a 
preparation with ‘0.75 litres of fluid and 12 hours fasting’, that did not influence preferences of CRC 
screening participants.  
The results of the sensitivity analyses indicated that removing respondents who failed the 
rationality test did not entail drastic changes in the outcomes of those analyses. We therefore included 
them in our further analyses.   
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The differences in preferences between screening naïve-individuals and participants of a CRC 
screening programme were statistically not significant, except for preferences regarding risk reduction 
of CRC related death. Screening naïve individuals demanded more effectiveness from a CRC 
screening programme compared to participants (p<0.01). We performed subgroup analyses, analysing 
FOBT and FS screenees separately, which showed that participants of FOBT and FS screening did 
differ in preferences: FS screenees expressed a positive attitude, while FOBT screenees expressed a 
negative attitude towards a test in the hospital (p<0.001). Furthermore, FS screenees attached more 
importance to a 5-yearly screening interval (p=0.01) and to the effectiveness of a screening test 
(p<0.001) than FOBT screenees.  
When comparing those with previous endoscopy experience to those without endoscopy 
experience, it could be seen that pain had a significant greater influence on preferences for those 
without previous endoscopy experience (p=0.02). The location hospital was negatively associated with 
preferences for those without endoscopy experience, but it had a positive affect on preferences for 
those who had undergone a previous endoscopy (difference: p<0.01). Individuals without endoscopy 
experience also demanded more effectiveness from a screening test (p<0.01).   
Screening-naïve individuals and CRC screening participants significantly preferred no 
preparation to all other preparations (p-values <0.03). Both groups significantly preferred preparation 
with an ‘enema’ or ‘0.75 litres of fluid’ instead of a preparation with ‘4 litres of fluid’ (p-values <0.001). 
Preparation with an ‘enema’ and ‘0.75 litres of fluid’ were valued equally by both groups (p-
values>0.09). 
 
Trade-offs 
It can be seen in Table 4 that, based on the expressed preferences, screening-naïve individuals 
required an additional relative risk reduction of 30% (95% confidence interval (CI) 24-37%) for 
participation in a screening programme with a test requiring a preparation with ‘4 litres of fluid and 18 
hours fasting’ instead of a test that required ‘no preparation’. Respondents preferred shorter screening 
intervals and they were willing to give up a 12% (CI 7-18%) relative risk reduction if the screening 
interval was shortened from once every 10 years to a 2-yearly screening interval. Participants of a 
CRC screening programme made trade-offs that were comparable to those of the screening naïve 
individuals.  
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Expected uptake of CRC screening 
The average expected uptake of CRC screening was 56% (CI 50 - 62%) for screening naïve 
individuals. Assuming that all screening tests would generate a 10% risk reduction of CRC related 
death, uptake would be 72% for biennial FOBT screening, 46% for 5-yearly FS screening and 22% for 
10-yearly colonoscopy screening. We would expect that, if individuals are aware of the achievable risk 
reduction as currently known from the literature, the uptake would increase to 75% for biennial FOBT 
screening, 80% for five-yearly FS screening and 71% for 10-yearly colonoscopy screening (risk 
reduction of CRC related death respectively 16% (34), 59% (5) and 74.5% (35)). The effects of 
changing the CRC screening programme characteristics on average expected uptake of CRC 
screening are shown in Figure 3.  
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Discussion 
Our study demonstrates the importance of several procedural characteristics of CRC screening 
programmes for the preferences of potential and actual screenees: risk reduction of CRC-related 
death, preparation for the procedure, procedure related pain and complications and screening interval. 
To optimise a screening programme, the attendance rate should be high. A high attendance rate is 
only possible when the utilised screening strategy and the information given connect with the 
preferences of the target population. The results of this DCE in the first place indicate targets for 
improvement of CRC screening programmes. Secondly they stress the importance of several aspects 
of screening programmes regarding the information provided to screening invitees. To our knowledge, 
this is the first study assessing preferences for CRC screening among both screening-naïve subjects 
and CRC screening participants.  
In our study, especially mortality reduction had an important positive influence on preferences for 
CRC screening methods. A few other studies have investigated preferences for CRC screening using 
a DCE. (36-41) Our finding that individuals attach much importance to CRC mortality reduction by a 
screening method is consistent with the results of previous studies. (36;41;42) The finding that 
individuals are prepared to undergo more burdensome screening tests if this results in sufficient 
additional risk reduction of CRC related mortality demonstrates that they trade benefits and harms of a 
screening test.  
The burden of the required preparation was considered the main drawback of undergoing CRC 
screening. A preparation commonly used for colonoscopy (i.e. drinking 4 litres of fluid and 18 hours 
fasting) would only be chosen when an additional relative risk reduction of, on average, 33% would be 
achieved. In line with our results, Canadian investigators found that preparation was ranked as the 
most important process related attribute. In contrast, American investigators found that preparation 
was rated as the least important attribute. (37) The levels that were chosen for the attributes may 
explain those differences. The results of our DCE are of utmost importance when for example starting 
a colonoscopy screening programme with a burdensome preparation. Emphasis should be laid on 
adequate information that should be provided to the target population about the burden and benefits 
including expected CRC mortality reduction by colonoscopy screening, since this may compensate for 
a burdensome preparation. 
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Interestingly, we found that respondents significantly preferred shorter screening intervals to a 10-
year screening interval irrespective of health benefit. This finding is consistent with a previous study 
suggesting that women preferred shorter (annual and biennial) over longer (3-, 4- or 5-year) screening 
intervals for cervical cancer screening. (43) One study among Danish individuals and another among 
both American and Canadian individuals could not confirm preferences for shorter CRC screening 
intervals. (36;40) A second American study could not determine if individuals preferred shorter or 
longer screening intervals. (37) Several studies have showed that reassurance may be a motivation 
for and/or a result of undergoing cancer screening. (44;45) The preference for shorter screening 
intervals found in our study may be associated with expected reassurance. This again stresses the 
importance of adequate information provided to potential screenees. It emphasises the need to 
adequately inform individuals that longer screening intervals for CRC screening do not imply lower 
reductions in mortality, but that specific CRC screening tests with longer screening intervals have 
more potential for CRC prevention and therefore require less frequent testing. 
There were some differences in preferences between FOBT and FS screenees. Assessment of 
preference variations across subgroups is advisory because of status quo bias; in other words the 
tendency of people to value services higher once they have experienced them. (46) We conducted the 
study among both screening-naïve individuals and individuals who had prior experience with CRC 
screening tests, so that we were able to investigate if status quo bias was present. The preferences of 
screening-naïve subjects and CRC screening participants were not significantly different. The fact that 
FOBT screenees expressed a negative attitude towards a test in the hospital, while FS screenees 
expressed a positive attitude towards a test in the hospital may be explained by the phenomenon of 
status quo bias. However, it may also be a result of selection bias; that those subjects with a 
preference for the location ‘home’ do not participate in FS screening and vice versa. Interestingly, the 
same significant difference regarding the influence of screening location on preferences was observed 
when comparing those with endoscopy experience to those without. A possible explanation might be 
that individuals on beforehand have a negative association with the location hospital, but develop a 
positive attitude towards a hospital-based examination once they have experienced it.   
Research has consistently shown that expected pain is one of the most important reasons for 
declining the endoscopic screening offer. (18;47;48) The results from our study confirm that finding 
and furthermore they demonstrate that pain has significant less influence on preferences of those with 
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endoscopy experience, suggesting that pain actually experienced during endoscopic screening is not 
as severe as expected on beforehand.  
This study revealed uptake levels of the FOBT, FS and colonoscopy based on the characteristics 
in our model. The uptake levels for FOBT and FS as predicted by our model are somewhat higher 
than observed in the Dutch screening trial conducted in the same target population (13), however 
participants in this trial were not informed on achievable risk reduction of CRC related death and the 
required frequency of testing for FOBT and FS which have both shown to positively influence CRC 
screening preferences. We found that mainly risk reduction of CRC related death highly influenced the 
participation that could be expected for the different screening tests, suggesting that increasing 
awareness on efficacy of the screening tests might enhance uptake.  
Given the low levels of awareness of CRC screening in the Netherlands, it may be of vital 
importance to raise knowledge on achievable risk reduction of CRC related death in order to increase 
screening uptake especially for the more effective endoscopic screening tests. The importance of 
awareness on efficacy of the available screening tests is further underlined by data of a Swiss study, 
in which 75% of all screenees chose to undergo a colonoscopy and only 25% preferred FOBT or FS 
screening after they were informed about the efficacy of all screening methods (49).This study 
involved testimonies from patients with CRC in their campaign in order to raise CRC awareness. This 
strategy has also been used in various other campaigns throughout the European Union, among 
others in the United Kingdom, Germany and the Netherlands. CRC patients and their relatives may be 
important advocates for raising awareness, and possibly also for increasing public familiarity with 
endoscopic screening which has been demonstrated to influence CRC screening preferences in our 
study. 
 There are some limitations to our study. There was a significant difference in response rate 
between screening-naïve individuals and CRC screening participants. This may have given a selection 
bias and thereby be a limitation regarding the interpretation of our results.  
Furthermore, the way we framed the information on risk reduction may have influenced our 
results. In order to minimise framing effects we attempted to frame our information, where possible, 
according to the current literature. (50) 
In conclusion, individuals are willing to trade-off benefits and harms of CRC screening 
programmes. Especially type of bowel preparation, length of screening interval and mortality reduction 
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influenced individuals’ trade-offs. The results provide insight in the decision-making process regarding 
the decision to participate in a CRC screening programme. This information can be used to improve 
information provided to CRC screening invitees, and identify targets for increasing participation rates.  
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Table 1:   Attributes and levels for colorectal cancer (CRC) screening 
 
Attributes and levels Beta coefficients in regression analysis 
Pain 
    No pain (reference level) 
    Mild pain     
 
 
β1 
Risk of complications 
    None (reference level) 
    Small 
 
 
β2 
Location 
    At home (reference level) 
    Hospital 
 
 
β3 
Preparation 
    None (reference level) 
    Enema. no fasting 
    Drinking of 0.75 litre of fluid. 12 hours fasting 
    Drinking of 4 litres of fluid. 18 hours fasting    
 
 
β4 β5 β6 
Duration 
    10 minutes  
    30 minutes 
    60 minutes 
    90 minutes 
 
β7 
Interval 
    1x in 10 years (reference level) 
    2x in 10 years 
    5x in 10 years 
    10x in 10 years 
 
 
β8 β9 
β10 
Risk reduction of death from CRC 
    3%  2.7% (10% relative risk reduction)  
    3%  1.8% (40% relative risk reduction) 
    3%  1.2% (60% relative risk reduction) 
    3%  0.3% (90% relative risk reduction) 
 
β11 
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Table 2: Respondent characteristics  
 
Characteristics Screening naïve Participants Difference 
Response (n respondents/n invited - %) 156/500 (31.0) 124/210 (59.0) p<0.01 
Analyzable questionnaires (n - %) 152 (97.4) 120 (96.8) p=0.74 
Age (mean – standard deviation (SD)) 59.9 (5.7) 62.2 (6.4) p<0.01 
Gender (male; n - %) 74 (48.7) 59 (49.2) p=0.94 
Socio economic status (n - %) 
        High 
        Intermediate  
        Low 
 
78 (51.3) 
21 (13.8) 
53 (34.9) 
 
53 (44.2) 
20 (16.7) 
47 (39.2) 
p=0.49 
Endoscopy experience (n - %) 
        Yes 
        No 
        Unknown 
 
33 (21.7) 
117 (77.0) 
2 (1.3) 
 
64 (53.3) 
54 (45.0) 
2 (1.6) 
p<0.01 
Knowing someone affected by colorectal cancer (CRC) (n - %) 
        Yes 
        No 
        Unknown 
 
19 (12.5) 
115 (75.7) 
18 (11.8) 
 
18 (15.0) 
88 (73.3) 
14 (11.6) 
p=0.84 
Generic health status (EQ-5D) summary score (mean - SD) 0.92 (0.11) 0.93 (0.12) p=0.48 
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Table 3: Preferences of the screening naïve individuals and participants of a colorectal cancer (CRC) screening programme 
 
Levels Screening naïve Participants 
 β-coefficient 95% confidence 
interval 
β -coefficient 95% confidence 
interval 
Constant (screening)  0.25 (-0.00 to 0.50)  0.62 (0.35 to 0.90)* 
Pain 
    No pain (ref) 
    Mild pain     
 
 
-0.31 
 
 
(-0.42 to -0.20)* 
 
 
-0.23 
 
 
(-0.34 to -0.11)* 
Risk of complications 
    None (ref) 
    Small 
 
 
-0.16 
 
 
(-0.28 to -0.05)* 
 
 
-0.13 
 
 
(-0.25 to -0.01)* 
Location 
    At home (ref) 
    Hospital 
 
 
-0.09 
 
 
(-0.20 to 0.02) 
 
 
-0.01 
 
 
(-0.13 to 0.10)* 
Preparation 
    None (ref) 
    Enema. no fasting 
    Drinking of 0.75 liter of fluid. 12 hours fasting 
    Drinking of 4 liters of fluid. 18 hours fasting    
 
 
-0.37 
-0.51 
-0.98 
 
 
(-0.57 to -0.16)* 
(-0.72 to -0.29)* 
(-1.18 to -0.77)* 
 
 
-0.23 
-0.22 
-0.88 
 
 
(-0.45 to -0.02)* 
      (-0.45 to 0.01)    
(-1.10 to -0.67)* 
Duration 
    None  
    Per 10 minutes spent in the screening process 
 
 
-0.03 
 
 
(-0.05 to -0.01)* 
 
 
-0.03 
 
 
(-0.06 to -0.01)* 
Interval 
    1x in 10 years (ref) 
    2x in 10 years 
    5x in 10 years 
    10x in 10 years 
 
 
0.28 
0.40 
0.33 
 
 
(0.11 to 0.45)* 
(0.21 to 0.59)* 
(0.18 to 0.49)* 
 
 
0.24 
0.33 
0.27 
 
 
(0.06 to 0.42)* 
(0.13 to 0.53)* 
(0.10 to 0.44)* 
Risk reduction of death from CRC 
    None  
    Per relative 10% risk reduction 
 
 
0.32 
 
 
(0.29 to 0.35)* 
 
 
0.26 
 
 
(0.24 to 0.29)* 
 
* significant at the 5% level 
(ref) = reference level 
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Table 4: Individuals’ tradeoffs between risk reduction and different aspects of a colorectal cancer (CRC) screening programme 
 
(ref) = reference level 
 
 
Levels Screening naïve Participants Interpretation note 
 % of additional relative risk reduction 
respondents think a test should generate.... 
 
Pain 
    None (ref) 
    Mild pain     
 
 
10% (6-13%) 
 
 
9% (4-13%) 
.. in order to undergo a test that causes mild pain instead 
of a test that causes no pain  
Risk of complications 
    None (ref) 
    Small 
 
 
5% (1-9%) 
 
 
5% (0-10%) 
.. in order to undergo a test that carries a small risk of 
complications instead of a test with no risk of 
complications 
Preparation 
    No preparation (ref) 
    Enema. no fasting 
    Drinking of 0.75 liter of fluid and 
        12 hours fasting 
    Drinking of 4 liters of fluid and  
        18 hours fasting    
 
 
11% (2-5%) 
16% (9-23%) 
 
30% (24-37%) 
 
 
9% (1-17%) 
8% (0-17%) 
 
33% (25-41%) 
 
 
.. in order to accept a test that requires a preparation with 
one of these three methods instead of a test requiring no 
preparation at all 
Duration 
    None  
    For each additional 10 minutes spent 
       in the screening process 
 
 
1% (0-2%) 
 
 
1% (0-2%) 
 
.. in order to accept a test with an additional 10 minutes 
of duration compared to the standard duration 
Interval 
    1x in 10 years (ref) 
    2x in 10 years 
    5x in 10 years 
    10x in 10 years 
 
 
9% (3-14%) 
12% (7-18%) 
10% (5-15%) 
 
 
9% (2-16%) 
13% (5-20%) 
10% (5-16%) 
.. if the screening interval is lengthened from one of the 
shorter, more preferred, screening intervals (5-yearly, 
biennial, annual) to the longest screening interval (once 
every 10 years) 
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